Indeed, high expression of DDR1 has also been identified in 52.2% of hepatocellular carcinoma samples [43], 61.0% of non-small cell lung cancer [13], and 69% of serous ovarian cancer tissues [15]. Here, DDR1 is linked to ovarian serous adenocarcinoma.